Circulating beta-atrial natriuretic factor in congestive heart failure in humans.
- 1 September 1993
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation
- Vol. 88 (3), 1016-1020
- https://doi.org/10.1161/01.cir.88.3.1016
Abstract
BACKGROUND beta-Atrial natriuretic factor (beta-ANF) is an antiparallel dimer of alpha-ANF (alpha-ANF) with diminished cyclic GMP generation in vitro. To date, the presence of beta-ANF in the circulation of humans with severe congestive heart failure (CHF) remains controversial. The current study was designed to determine the presence and magnitude of circulating beta-ANF in severe CHF, to correlate plasma beta-ANF with the degree of ventricular dysfunction, and to investigate the role of human plasma and atrial tissue in the degradation of beta-ANF. METHODS AND RESULTS Venous plasma samples were obtained from patients (n = 12) with severe CHF and normal volunteers (n = 8). Total plasma ANF was measured by radioimmunoassay. alpha-ANF and beta-ANF in nonextracted plasma were separated by gel filtration chromatography using a P-6 column. Right atrial tissue samples (n = 5) were collected from a different group of patients at the time of open-heart surgery. 125I beta-ANF and I125 ANF were incubated with atrial tissue or plasma. The corresponding peak areas of beta-ANF were determined by Tamaya Digital Planimeter. beta-ANF represented 61% of total plasma ANF in CHF patients and was not detected in normal human plasma. The elevation of beta-ANF correlated with the severity of ventricular dysfunction. Thirty percent of beta-ANF and 100% alpha-ANF were converted to smaller peptide fragments in atrial tissue no conversion in plasma. CONCLUSIONS beta-ANF is the principal form of circulating ANF in patients with severe CHF and correlates with the degree of left ventricular dysfunction. beta-ANF is not generated from alpha-ANF and may be degraded rapidly in atrial tissue to smaller peptide fragments that do not occur in plasma. As beta-ANF is reported to have reduced biological action, the current studies may support the conclusion that the ANF system in CHF has reduced functional activity despite increases in circulation concentrations.Keywords
This publication has 22 references indexed in Scilit:
- A dicarba analog of β‐atrial natriuretic peptide (β‐ANP) inhibits guanosine 3′,5′‐cyclic monophosphate production induced by α‐ANP in cultured rat vascular smooth muscle cellsFEBS Letters, 1989
- Changes of molecular forms of atrial natriuretic peptide after treatment for congestive heart failureKlinische Wochenschrift, 1988
- Augmented synthesis of β-human atrial natriuretic polypeptide in human failing heartsBiochemical and Biophysical Research Communications, 1988
- Molecular forms of atrial natriuretic polypeptides circulating in human plasmaBiochemical and Biophysical Research Communications, 1986
- Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion.Journal of Clinical Investigation, 1986
- Molecular forms of atrial natriuretic polypeptides in mammalian tissues and plasmaBiochemical and Biophysical Research Communications, 1985
- Structural identification of β- and γ-human atrial natriuretic polypeptidesNature, 1985
- Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide (α-hANP)Biochemical and Biophysical Research Communications, 1984
- The amino acid sequence of an atrial peptide with potent diuretic and natriuretic propertiesBiochemical and Biophysical Research Communications, 1983
- A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in ratsLife Sciences, 1981